Dr. Ruben Joseph Mylvaganam, MD

Dr. Mylvaganam practices at Northwestern Medical Group in Chicago, Illinois.

Dr. Mylvaganam's NPI, 1629462676, was assigned on March 26, 2015. Dr. Mylvaganam graduated from New York University School of Medicine in 2015. Dr. Mylvaganam holds Illinois license 036146223.

Dr. Mylvaganam's primary practice is Northwestern Medical Group, at 675 N Saint Clair St Ste 19-100 Suite 19-100, Chicago, IL 60611. The practice phone is (312) 664-3278.

Dr. Mylvaganam's primary practice is Northwestern Medical Group in Chicago, Illinois. Dr. Mylvaganam is also affiliated with Northwestern Memorial Hospital. The medical group on file is Northwestern Medical Faculty Foundation. Dmand AI also links Dr. Mylvaganam to 4 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mylvaganam practices, 7 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Mylvaganam's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Mylvaganam is licensed in Illinois.

CMS data shows 1,099 Medicare services from Dr. Mylvaganam across 18 procedure codes in 2024, for 295 Medicare patients. Medicare paid $99,640 for them.

CMS counts 295 Medicare patients who saw Dr. Mylvaganam in 2024. The largest group is 65 to 74, with 119 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 24% are also on Medicaid. Their average risk score is 2.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mylvaganam's median patient age at 72, with 61% women.

In 2024, Dr. Mylvaganam wrote 892 Medicare Part D claims for 88 patients. 33% of them were for generic drugs. CMS names the drug for 816 of them, across 14 drugs with 11 or more claims each, at $6,931,047 in total drug cost. In 2023, CMS named 499 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Mylvaganam for performance year 2024, reported through an alternative payment model (APM). Dr. Mylvaganam accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mylvaganam as offering telehealth.

Dmand AI links 18 papers to Dr. Mylvaganam, published from 2017 to 2025. 2023 was the busiest year, with 5. The most frequent topics are SARS-CoV-2, Antiviral Agents and COVID-19. Dr. Mylvaganam has published most often in Crit Care Explor. Dr. Mylvaganam's most frequent co-authors are Michael J. Cuttica, MD, Ryan J. Avery, MD and Daniel Richard Schimmel, MD, MS.

CMS Open Payments shows 87 general payments to Dr. Mylvaganam from 4 drug and device companies from 2021 to 2025. Consulting fees make up the largest share, 64% of the total. United Therapeutics Corporation paid the most, $14,486.

Dr. Mylvaganam graduated from New York University School of Medicine in 2015.